Upregulation of HLA-Class I and II in Placentas Diagnosed with Villitis of Unknown Etiology

被引:0
|
作者
Elizabeth Ann L. Enninga
Alexey A. Leontovich
Bohdana Fedyshyn
Laurie Wakefield
Manish Gandhi
Svetomir N. Markovic
Rodrigo Ruano
Sarah E. Kerr
机构
[1] Mayo Clinic,Department of Obstetrics and Gynecology
[2] Mayo Clinic,Department of Health Science Research
[3] Mayo Clinic,Department of Transfusion Medicine
[4] Mayo Clinic,Department of Immunology
[5] Mayo Clinic,Department of Laboratory Pathology
来源
Reproductive Sciences | 2020年 / 27卷
关键词
Placenta; HLA; Villitis; Inflammation; Rejection;
D O I
暂无
中图分类号
学科分类号
摘要
The placenta utilizes many mechanisms to protect the haploidentical fetus from recognition by the maternal immune system. However, in cases of villitis of unknown etiology (VUE), maternal lymphocytes gain access into the placenta, causing significant health risks for the fetus. Evidence suggests that VUE is a rejection response between the mother and the haploidentical fetus. Therefore, we profiled human leukocyte antigen (HLA), an important predictor of transplant rejection, in VUE using placental tissue from ten patients with VUE and ten gestational age matched controls. Placentas were stained using novel multiplexed immunofluorescence (MxIF) to investigate morphology and HLA classes I and II. Gene expression was evaluated by microarray, and where available, tissue typing of mother/baby pairs was completed to determine HLA type. MxIF demonstrated strong CD8+ T cell infiltration and HLA class I staining both the distal and stem villi of VUE placentas. Compared to controls, VUE cases had significantly higher expression of HLA class II mRNA and pathway analysis demonstrated that 40% of the differentially expressed genes in VUE are related to tissue rejection. The data suggest that VUE resembles a rejection response between the mother and the fetus. It remains unknown what initiates immune recognition and why some mothers appear to be at higher risk for developing this condition than others. Understanding this etiology will be critical for developing effective interventions or prevention strategies during pregnancy.
引用
收藏
页码:1129 / 1138
页数:9
相关论文
共 50 条
  • [1] Upregulation of HLA-Class I and II in Placentas Diagnosed with Villitis of Unknown Etiology
    Enninga, Elizabeth Ann L.
    Leontovich, Alexey A.
    Fedyshyn, Bohdana
    Wakefield, Laurie
    Gandhi, Manish
    Markovic, Svetomir N.
    Ruano, Rodrigo
    Kerr, Sarah E.
    REPRODUCTIVE SCIENCES, 2020, 27 (05) : 1129 - 1138
  • [2] IMMUNOLOGICAL STUDIES IN PLACENTAS WITH VILLITIS OF UNKNOWN ETIOLOGY - COMPLEMENT COMPONENTS AND IMMUNOGLOBULINS IN CHORIONIC VILLI
    ALTEMANI, AM
    NORATO, D
    BAUMEL, C
    JOURNAL OF PERINATAL MEDICINE, 1992, 20 (02) : 129 - 134
  • [3] Distinct patterns of C4d immunoreactivity in placentas with villitis of unknown etiology, cytomegaloviral placentitis, and infarct
    Lee, K. A.
    Kim, Y. W.
    Shim, J. -Y.
    Won, H. -S.
    Lee, P. R.
    Kim, A.
    Kim, C. J.
    PLACENTA, 2013, 34 (05) : 432 - 435
  • [4] Virtual crossmatching reveals upregulation of placental HLA-Class II in chronic histiocytic intervillositis
    Brady, Chloe A.
    Ford, Laura B.
    Moss, Chloe
    Zou, Zhiyong
    Crocker, Ian P.
    Heazell, Alexander E. P.
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [5] HLA-class II and class I genotypes among Japanese children with Type 1A diabetes and their families
    Sugihara, Shigetaka
    Ogata, Tsutomu
    Kawamura, Tomoyuki
    Urakami, Tatsuhiko
    Takemoto, Koji
    Kikuchi, Nobuyuki
    Takubo, Noriyuki
    Tsubouchi, Kohji
    Horikawa, Reiko
    Kobayashi, Kisho
    Kasahara, Yoshihito
    Kikuchi, Tohru
    Koike, Akemi
    Mochizuki, Takahiro
    Minamitani, Kanshi
    Takaya, Ryuzo
    Mochizuki, Hiroshi
    Nishii, Aki
    Yokota, Ichiro
    Kizaki, Zenro
    Mori, Tetsuo
    Shimura, Naoto
    Mukai, Tokuo
    Matsuura, Nobuo
    Fujisawa, Takao
    Ihara, Kenji
    Kosaka, Kitaro
    Kizu, Rika
    Takahashi, Toshikazu
    Matsuo, Satoshi
    Hanaki, Keiichi
    Igarashi, Yutaka
    Sasaki, Goro
    Soneda, Shun
    Teno, Shinichi
    Kanzaki, Susumu
    Saji, Hiroh
    Tokunaga, Katsushi
    Amemiya, Shin
    PEDIATRIC DIABETES, 2012, 13 (01) : 33 - 44
  • [6] HLA-Class II in Latin American patients with type 1 diabetes
    Rojas-Villarraga, Adriana
    Botello-Corzo, Diana
    Anaya, Juan-Manuel
    AUTOIMMUNITY REVIEWS, 2010, 9 (10) : 666 - 673
  • [7] HLA-class I antibodies in PLT-monospecific alloimmunized patients
    Moncharmont, P.
    Giannoli, C.
    Vignal, M.
    Dubois, V.
    Rigal, D.
    IMMUNO-ANALYSE & BIOLOGIE SPECIALISEE, 2007, 22 (02): : 111 - 114
  • [8] Macrophages and HLA-Class II Alleles in Multiple Sclerosis: Insights in Therapeutic Dynamics
    Prapas, Petros
    Anagnostouli, Maria
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (13)
  • [9] A susceptibility region for myasthenia gravis extending into the HLA-class I sector telomeric to HLA-C
    Janer, M
    Cowland, A
    Picard, J
    Campbell, D
    Pontarotti, P
    Newsom-Davis, J
    Bunce, M
    Welsh, K
    Demaine, A
    Wilson, AG
    Willcox, N
    HUMAN IMMUNOLOGY, 1999, 60 (09) : 909 - 917
  • [10] Antibody verification of HLA class I and class II eplets by human monoclonal HLA antibodies
    Kramer, Cynthia S. M.
    Bezstarosti, Suzanne
    Franke-van Dijk, Marry E. I.
    Vergunst, Manon
    Roelen, Dave L.
    Uyar-Mercankaya, Merve
    Voogt-Bakker, Kim H.
    Heidt, Sebastiaan
    HLA, 2024, 103 (01)